MyHizentra™ Infusion Manager App

Under the direction of your prescriber, the MyHizentra Infusion Manager app can help patients / caregivers schedule infusions, get reminders about upcoming infusions, and record details of each infusion.

Your Digital Hizentra Therapy & Infusion Manager

Introducing a way to stay on track with your therapy! The MyHizentra Infusion Manager app is here to help you schedule your infusions, alert you when it's time to infuse, and simplify the infusion tracking process.

Mobile app that allows patients to set up custom alerts for self-administration treatments

Custom Self-Infusion Reminders

Rather than just receiving a single reminder on a single device, the MyHizentra Infusion Manager app can send you reminders on all cloud-synced devices (desktop, laptop, mobile phone) as part of your regular calendar. This makes it easier to remember and keep your infusion appointments.

Infusion Manager app that assists in managing infusions with a customizable schedule and preferences

Flexible & Designed With You in Mind

Like Hizentra itself, the Infusion Manager app is flexible and designed to fit your lifestyle. Whether you are managing your own infusions or those of a loved one, you can adjust the schedule and the reminder times for your convenience. You can even reschedule the infusion time if you are aware of a conflict during the scheduled time. Adjustments to your schedule should only be made under the supervision of your prescriber.

Multiple users can access the app from one device, but each user has a separate profile within the app. This makes it simple, since the infusion schedule and preferences can be customized for each user.

Mobile app that stores a detailed record of infusions

Keep a Detailed Record of Every Infusion

The app makes it easy for you to record your infusions, including scanning the QR code of each vial and giving you a place to write notes about each infusion. The infusion journal records the date, time, infusion sites, how you were feeling, any other medications you are taking, and other notes. You'll be able to review the digital record of your past infusions at any time, which will make it convenient to discuss your infusion experiences with your doctor during appointments. Also, in the event of a vial recall or alert, your entire infusion history can be searched for the affected lot.

Apple, the Apple logo, iPad, and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. By clicking on the App Store link above, you will be taken to a website hosted by Apple.

Android and Google Play are trademarks of Google Inc. By clicking on the Google Play link above, you will be taken to a site hosted by Google Inc.

Important Safety Information

Important Safety Information

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Patient/Caregiver Resources Hizentra Infusion App
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ/09-12-0016k(1) 9/2015